{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:11:42Z","timestamp":1793261502161,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-cardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiology"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.jjcc.2019.03.001","type":"journal-article","created":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T02:13:54Z","timestamp":1553134434000},"page":"49-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Arginine vasopressin antagonism in heart failure: Current status and possible new directions"],"prefix":"10.1016","volume":"74","author":[{"given":"Steven R.","family":"Goldsmith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jjcc.2019.03.001_bib0115","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1253\/jcj.32.745","article-title":"level in patients with chronic congestive heart failure","volume":"32","author":"Yamane","year":"1968","journal-title":"Jpn Circ J"},{"key":"10.1016\/j.jjcc.2019.03.001_bib0120","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1056\/NEJM198107303050506","article-title":"Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure","volume":"305","author":"Szatalowicz","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2019.03.001_bib0125","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0735-1097(83)80040-0","article-title":"Increased plasma arginine vasopressin levels in patients with congestive heart failure","volume":"1","author":"Goldsmith","year":"1983","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2019.03.001_bib0130","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1071-9164(99)91339-8","article-title":"Vasopressin: a therapeutic target in congestive heart failure?","volume":"5","author":"Goldsmith","year":"1999","journal-title":"J Card Fail"},{"key":"10.1016\/j.jjcc.2019.03.001_bib0135","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2019.03.001_bib0140","doi-asserted-by":"crossref","first-page":"370","DOI":"10.7326\/0003-4819-101-3-370","article-title":"The neurohumoral axis in congestive heart failure","volume":"101","author":"Francis","year":"1984","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jjcc.2019.03.001_bib0145","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S0735-1097(86)80333-3","article-title":"Contribution of vasopressin to vasoconstriction in patients with congestive heart failure: comparison with the renin-angiotensin system and the sympathetic nervous system","volume":"7","author":"Creager","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2019.03.001_bib0150","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0735-1097(86)80417-X","article-title":"Hemodynamic effects of infused arginine vasopressin in congestive heart failure","volume":"8","author":"Goldsmith","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2019.03.001_bib0155","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","article-title":"Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial","volume":"297","author":"Konstam","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jjcc.2019.03.001_bib0160","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.cardfail.2013.04.001","article-title":"Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan","volume":"19","author":"Hauptman","year":"2013","journal-title":"J Card Fail"},{"key":"10.1016\/j.jjcc.2019.03.001_bib0165","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1161\/CIRCHEARTFAILURE.113.000828","article-title":"Decongestive therapy and renal function in acute heart failure: time for a new approach?","volume":"7","author":"Goldsmith","year":"2014","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jjcc.2019.03.001_bib0170","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/0002-8703(83)90039-X","article-title":"The acute response of plasma norepinephrine, renin activity, and arginine vasopressin to short-term nitroprusside and nitroprusside withdrawal in patients with congestive heart failure","volume":"106","author":"Francis","year":"1983","journal-title":"Am Heart J"},{"key":"10.1016\/j.jjcc.2019.03.001_bib0175","doi-asserted-by":"crossref","first-page":"F273","DOI":"10.1152\/ajprenal.00195.2005","article-title":"Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure","volume":"290","author":"Costello-Boerrigter","year":"2006","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.jjcc.2019.03.001_bib0180","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/ehf2.12088","article-title":"Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure","volume":"3","author":"Jujo","year":"2016","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jjcc.2019.03.001_bib0185","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.cardfail.2011.08.005","article-title":"A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction","volume":"17","author":"Udelson","year":"2011","journal-title":"J Card Fail"},{"key":"10.1016\/j.jjcc.2019.03.001_bib0190","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1161\/CIRCHEARTFAILURE.112.970012","article-title":"Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST Trial","volume":"6","author":"Lanfear","year":"2012","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jjcc.2019.03.001_bib0195","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/jama.291.16.1963","article-title":"Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial","volume":"291","author":"Gheorghiade","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jjcc.2019.03.001_bib0200","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jacc.2016.09.004","article-title":"Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure","volume":"69","author":"Felker","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2019.03.001_bib0205","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.jacc.2016.12.035","article-title":"Short-term effects of tolvaptan in patients with acute heart failure and volume overload","volume":"69","author":"Konstam","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2019.03.001_bib0210","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.cardfail.2016.02.007","article-title":"Clinical effectiveness of tolvaptan in patients with acute heart failure and renal dysfunction","volume":"22","author":"Matsue","year":"2016","journal-title":"J Card Fail"},{"key":"10.1016\/j.jjcc.2019.03.001_bib0215","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.cardfail.2008.06.003","article-title":"Efficacy and safety of the vasopressin V1A\/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study","volume":"14","author":"Goldsmith","year":"2008","journal-title":"J Card Fail"},{"key":"10.1016\/j.jjcc.2019.03.001_bib0220","first-page":"620","article-title":"Get the right balance: a novel vasopressin receptor antagonist equally blocks human V1a and V2 receptors and inhibits the release of plasminogen activator inhibitor-1 from cardiomyocytes","volume":"37","author":"Kolkhof","year":"2016","journal-title":"Eur Heart J"}],"container-title":["Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S091450871930053X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S091450871930053X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:01:10Z","timestamp":1760274070000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S091450871930053X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S091450871930053X"],"URL":"https:\/\/doi.org\/10.1016\/j.jjcc.2019.03.001","relation":{},"ISSN":["0914-5087"],"issn-type":[{"value":"0914-5087","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Arginine vasopressin antagonism in heart failure: Current status and possible new directions","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jjcc.2019.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Japanese College of Cardiology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}